Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Insmed Inc has a consensus price target of $76.11 based on the ratings of 20 analysts. The high is $102 issued by Goldman Sachs on July 10, 2024. The low is $42 issued by Wolfe Research on February 15, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Truist Securities, and HC Wainwright & Co. on August 29, 2024, August 12, 2024, and August 12, 2024, respectively. With an average price target of $88.33 between HC Wainwright & Co., Truist Securities, and HC Wainwright & Co., there's an implied 18.78% upside for Insmed Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Insmed (NASDAQ:INSM) was reported by Cantor Fitzgerald on September 9, 2024. The analyst firm set a price target for $0.00 expecting INSM to fall to within 12 months (a possible -100.00% downside). 44 analyst firms have reported ratings in the last year.
The latest analyst rating for Insmed (NASDAQ:INSM) was provided by Cantor Fitzgerald, and Insmed reiterated their overweight rating.
There is no last upgrade for Insmed
There is no last downgrade for Insmed.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Insmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Insmed was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.
While ratings are subjective and will change, the latest Insmed (INSM) rating was a reiterated with a price target of $0.00 to $0.00. The current price Insmed (INSM) is trading at is $74.37, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.